Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

Abstract Background Hereditary angioedema (HAE) is a debilitating disorder resulting from C1-esterase inhibitor (C1-INH) deficiency. In the COMPACT phase 3 study the prophylactic use of a subcutaneous C1 inhibitor (C1-INH [SC], HAEGARDA®, CSL Behring) twice weekly significantly reduced the frequency...

Full description

Bibliographic Details
Main Authors: H. Henry Li, Bruce Zuraw, Hilary J. Longhurst, Marco Cicardi, Konrad Bork, James Baker, William Lumry, Jonathan Bernstein, Michael Manning, Donald Levy, Marc A. Riedl, Henrike Feuersenger, Subhransu Prusty, Ingo Pragst, Thomas Machnig, Timothy Craig, for the COMPACT Investigators
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
C1-esterase inhibitor protein
C1-INH (SC)
COMPACT study
HAEGARDA®
Hereditary angioedema
Long-term prophylaxis
Online Access:http://link.springer.com/article/10.1186/s13223-019-0362-1

Internet

http://link.springer.com/article/10.1186/s13223-019-0362-1

Similar Items